174 related articles for article (PubMed ID: 30025479)
21. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
22. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
23. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.
Bao B; Mitrea C; Wijesinghe P; Marchetti L; Girsch E; Farr RL; Boerner JL; Mohammad R; Dyson G; Terlecky SR; Bollig-Fischer A
Sci Rep; 2017 Mar; 7():44125. PubMed ID: 28281569
[TBL] [Abstract][Full Text] [Related]
24. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
[TBL] [Abstract][Full Text] [Related]
25. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
26. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
27. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
28. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway.
Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
30. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
32. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
33. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Fenn K; Maurer M; Lee SM; Crew KD; Trivedi MS; Accordino MK; Hershman DL; Kalinsky K
Clin Breast Cancer; 2020 Feb; 20(1):80-86. PubMed ID: 31570268
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
36. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
Zhang Y; Bi J; Zhu H; Shi M; Zeng X
Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
[TBL] [Abstract][Full Text] [Related]
37. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
[TBL] [Abstract][Full Text] [Related]
38. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
39. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Liu X; Adorno-Cruz V; Chang YF; Jia Y; Kawaguchi M; Dashzeveg NK; Taftaf R; Ramos EK; Schuster EJ; El-Shennawy L; Patel D; Zhang Y; Cristofanilli M; Liu H
Theranostics; 2021; 11(13):6632-6643. PubMed ID: 33995681
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
